<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491374</url>
  </required_header>
  <id_info>
    <org_study_id>P04909</org_study_id>
    <nct_id>NCT00491374</nct_id>
  </id_info>
  <brief_title>Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)</brief_title>
  <official_title>A Double-Blind Placebo-Controlled, Randomized, Parallel-Group, Single-Site Study Of Mometasone Furoate Nasal Spray (MFNS) In Subjects With Mild-Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) Associated With Perennial Allergic Rhinitis (PAR) Using Polysomnographic Recordings of Sleep Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Schering-Plough</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will hope to show that the treatment of the patient's perennial allergic rhinitis&#xD;
      (PAR) using Nasonex® (mometasone furoate nasal spray) will result in improvement of the nasal&#xD;
      symptoms of PAR and of nighttime sleep-disordered breathing, thereby resulting in improved&#xD;
      sleep quality, less daytime sleepiness, improved daytime functioning, and improved quality of&#xD;
      life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Very poor enrollment&#xD;
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change From Baseline in the Number of Apnea-hypopnea Episodes Per Hour (Apnea-hypopnea Index (AHI)</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>MFNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate Nasal Spray</intervention_name>
    <description>Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.</description>
    <arm_group_label>MFNS</arm_group_label>
    <other_name>SCH 32088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Nasal Spray 4 sprays once daily every morning for 28 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be 18 to 45 years of age, of either sex, and any race.&#xD;
&#xD;
          2. Must have at least a 2-year history of PAR.&#xD;
&#xD;
          3. Must be skin test positive for the usual allergens associated with PAR within the&#xD;
             previous 12 months with regular exposure to at least one of the allergens to which the&#xD;
             subject is allergic.&#xD;
&#xD;
          4. Must be sufficiently symptomatic at the Screening Visit (Visit 1), Qualification Visit&#xD;
             (Visit 2), and Baseline Visit (Visit 4) with a minimal level of PRIOR (reflective)&#xD;
             total symptom score, total nasal symptoms score, and total non-nasal symptoms score in&#xD;
             order to qualify.&#xD;
&#xD;
          5. At the Qualification Visit 2, subjects must have a score of at least 2 with the&#xD;
             Interference with Sleep severity rating score for at least 3 of the 7 nights prior to&#xD;
             the Qualification visit.&#xD;
&#xD;
          6. At the Baseline Visit 4 subjects must have a score of at least 2 with the Interference&#xD;
             with Sleep severity rating score for at least 1 of the 3 nights prior to the Baseline&#xD;
             Visit.&#xD;
&#xD;
          7. Must have an apnea-hypopnea index (AHI) of &gt;=5, but not more than 30, during the first&#xD;
             screening polysomnographic evaluation and to proceed to the second polysomnographic&#xD;
             evaluation.&#xD;
&#xD;
          8. At the Baseline Visit (Visit 4), the subjects must complete the NRQLQ, PQSI, ESS,&#xD;
             WPAI-AS.&#xD;
&#xD;
          9. Must complete the PVT within 1 hour of bedtime and 1 hour of arising on the nights&#xD;
             when the PSGs are done.&#xD;
&#xD;
         10. Female subjects of childbearing potential (including women who are less than 1 year&#xD;
             postmenopausal and women who will be sexually active during the study) must agree to&#xD;
             use a medically accepted method of contraception or be surgically sterilized prior to&#xD;
             screening, while receiving protocol-specified medication, and for 30 days after&#xD;
             stopping the medication. Women who are postmenopausal for &gt;1 year (ie, women who have&#xD;
             experienced 12 consecutive months of amenorrhea) will be exempted from the use of&#xD;
             contraception during the study.&#xD;
&#xD;
         11. Female subjects of childbearing potential must have a negative urine pregnancy test at&#xD;
             Screening (Visit 1) and a negative urine pregnancy test at Visit 4 confirmed prior to&#xD;
             dosing with the study drug and at final Visit 7.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has symptomatic seasonal allergic rhinitis (SAR) or a history of SAR during&#xD;
             the same calendar period as this study.&#xD;
&#xD;
          2. Subject is a female who is pregnant, or intends to become pregnant during the study.&#xD;
&#xD;
          3. Subject is nursing, or intends to be nursing during the study.&#xD;
&#xD;
          4. Subject has used any investigational product within 30 days prior to enrollment or any&#xD;
             antibodies for asthma or allergic rhinitis in the past 90 days).&#xD;
&#xD;
          5. Subject has any of the following clinical conditions:&#xD;
&#xD;
               -  known severe sleep apnea&#xD;
&#xD;
               -  asthma&#xD;
&#xD;
               -  chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
               -  alcohol abuse&#xD;
&#xD;
               -  rhinitis medicamentosa&#xD;
&#xD;
          6. Subject is currently on or has been on an antihistamine, decongestant (topical or&#xD;
             systemic) or a nasal inhaled corticosteroid during the 14 days prior to the Screening&#xD;
             Visit.&#xD;
&#xD;
          7. Subject with current or history of frequent episodes (2 or more episodes per year for&#xD;
             the past 2 years) of clinically significant sinusitis or chronic purulent postnasal&#xD;
             drip.&#xD;
&#xD;
          8. Subject has had recent nasal septum ulcers, nasal surgery, or nasal trauma.&#xD;
&#xD;
          9. Subject has had an upper or lower respiratory tract or sinus infection that required&#xD;
             antibiotic therapy with the last dose 14 days prior to screening, or who has had a&#xD;
             viral upper or lower respiratory infection within 14 days prior to screening.&#xD;
&#xD;
         10. Subject has nasal structural abnormalities, including large nasal polyps, and marked&#xD;
             septum deviation that significantly interfere with nasal airflow.&#xD;
&#xD;
         11. Subject is unable to refrain from regular use of nasal, oral or ocular decongestants,&#xD;
             nasal topical antihistamines, or nasal steroids.&#xD;
&#xD;
         12. Subject on immunotherapy (desensitization therapy) should not receive an increase in&#xD;
             dose during the study. Subjects may not receive desensitization treatment within 24&#xD;
             hours prior to a study visit.&#xD;
&#xD;
         13. Subject has active or quiescent tuberculosis infection of the respiratory tract,&#xD;
             untreated fungal, bacterial, or systemic viral infections, or ocular herpes simplex.&#xD;
&#xD;
         14. Subject is morbidly obese (BMI &gt;=35).&#xD;
&#xD;
         15. Subject is a night-shift worker and does not have a standard asleep at night / awake&#xD;
             during the day cycle, or has an irregular sleep/wake schedule.&#xD;
&#xD;
         16. Subject reports routinely spending less than 6 1/2 hours of time in bed per night.&#xD;
&#xD;
         17. Subject reports drinking 3 or more cups of regular coffee or 4 or more 8 ounce&#xD;
             cans/bottles of caffeine-containing carbonated beverages per 24 hour period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <results_first_submitted>November 26, 2008</results_first_submitted>
  <results_first_submitted_qc>January 5, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2009</results_first_posted>
  <last_update_submitted>January 5, 2009</last_update_submitted>
  <last_update_submitted_qc>January 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Head, Clinical Trials Registry &amp; Results Disclosure Group</name_title>
    <organization>Schering-Plough</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No subject fulfilled the requirements for randomized assignment of treatment; thus, no subject was assigned an intervention, and no subject was treated. The trial was terminated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
        </group>
        <group group_id="P2">
          <title>Mometasone Furoate Nasal Spray</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Mometasone Furoate Nasal Spray</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Any Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Either Sex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change From Baseline in the Number of Apnea-hypopnea Episodes Per Hour (Apnea-hypopnea Index (AHI)</title>
        <population>The primary outcome measure could not be assessed because no subject received randomized treatment assignment, or any treatment. The study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Mometasone Furoate Nasal Spray</title>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in the Number of Apnea-hypopnea Episodes Per Hour (Apnea-hypopnea Index (AHI)</title>
          <population>The primary outcome measure could not be assessed because no subject received randomized treatment assignment, or any treatment. The study was terminated.</population>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Mometasone Furoate Nasal Spray</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>any</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>This study was difficult to enroll subjects, and after 5 months of screening, the screen failure rate was 100%. At that time the decision was made to terminate the study. No subject was treated and no data were collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Head, Clinical Trials Registry &amp; Results Disclosure Group</name_or_title>
      <organization>Schering-Plough</organization>
      <email>ClinicalTrialsDisclosure@spcorp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

